Kodiak Sciences (FRA:K27) ROCE % : -47.46% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kodiak Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kodiak Sciences's annualized ROCE % for the quarter that ended in Sep. 2024 was -47.46%.

Kodiak Sciences ROCE % Historical Data

The historical data trend for Kodiak Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences ROCE % Chart

Kodiak Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-21.90

-18.80

-29.63

-47.65

-48.69

Kodiak Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-40.63	-51.48	-40.69	-45.90	-47.46

Kodiak Sciences ROCE % Calculation

Kodiak Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-238.858	/	( ( (629.297 - 49.556)	+	(439.584 - 38.265) )	/ 2 )
	=	-238.858	/	( (579.741	+	401.319)	/ 2 )
	=	-238.858	/	490.53
	=	-48.69 %

Kodiak Sciences's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-158.38	/	( ( (373.066 - 19.698)	+	(335.775 - 21.678) )	/ 2 )
	=	-158.38	/	( ( 353.368	+	314.097 )	/ 2 )
	=	-158.38	/	333.7325
	=	-47.46 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Kodiak Sciences (FRA:K27) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kodiak Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kodiak Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (FRA:K27) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

KOD:USA KOD:Mexico

Address

1200 Page Mill Road, Palo Alto, CA, USA, 94304

Website

https://www.kodiak.com

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Kodiak Sciences Headlines

No Headlines